Portola Pharmaceuticals to Announce Second Quarter 2017 Financial Results and Host Conference Call on Wednesday, August 9
02 août 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company’s...
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
27 juil. 2017 16h08 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on July 25, 2017, the Compensation Committee of the Board of...
Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Scientific and Standardization Committee Meeting
06 juil. 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif. , July 06, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that data on betrixaban and andexanet alfa, as well as presentations on...
U.S. FDA Approves Bevyxxa® (betrixaban) First and Only Anticoagulant for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
23 juin 2017 13h04 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced the U.S. Food and Drug Administration (FDA) has approved Bevyxxa...
Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma
15 juin 2017 08h30 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced the presentation of interim data from a Phase 2a study evaluating...
Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association (EHA)
18 mai 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 18, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that preclinical and clinical data on cerdulatinib in...
Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma (ICML)
09 mai 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that clinical results from the Phase 2 study of cerdulatinib in...
Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update
08 mai 2017 16h35 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today reported financial results and provided a corporate update for the quarter ended March...
Portola Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Monday, May 8
01 mai 2017 08h00 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) announced today that it will host a webcast and conference call to discuss the Company's...
Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17
07 mars 2017 16h05 HE
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that new data from the pivotal Phase 3 APEX Study of the...